Effect of Sulfation and Molecular Weight on Anticoagulant Activity of Dextran

Дрозд, Н. Н.; Logvinova, Yu.S.; Торлопов, М. А.; Udoratina, E. V.

doi:10.1007/s10517-017-3640-2

Cited by 16 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we know, effects of HBOCs on platelet aggregation or coagulation relates with the safety. However, Toussaint et al proposed that hemoglobin conjugated to macromolecules of dextran benzene tetracarboxylate did not alter platelet aggregation in vitro using flow cytometry [18] and Drozd et al [19] found that Dextran sulphates with molecular weights of 20 and 150 kDa did not potentiate ADP-induced human platelet aggregation. Referring to these articles, we suggest that Dex-bHb was counted as little impact on platelet aggregation.…”

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo investigation of the novel Dex-bHb as oxygen carriers

Zhang

Wang

Zhang

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The development of hemoglobin-based oxygen carriers (HBOCs) is a persistent and urgent need in biomedicine. As a potential HBOCs, Dextran-hemoglobin (Dex-bHb) has been developed over the past years. The novel Dex-bHb, whose thiol group of Cys-93(b) was reversibly protected, was produced and the characteristics were evaluated in our previous study. Herein, blood compatibility was characterized in terms of the red blood cell aggregation and hemolysis rate in vitro, and Dex-bHb showed no obvious effects. After intravenous administration of Dex-bHb to golden Syrian hamsters with hemorrhages shock, it showed mean arterial pressure recovery, blood flow increase and the organ protection from serious hemorrhage injury. Consequently, Dex-bHb is hopeful to be a safe and available blood substitute.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro and in vivo investigation of the novel Dex-bHb as oxygen carriers

Zhang

Wang

Zhang

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…According to the graph of the dependence of the plasma coagulation time on the concentration of NMIC derivatives, concentrations of 2APTT (mg/mL) were determined at which the plasma coagulation time was twice as long as in the control with the addition of 0.05 M Tris-HCl buffer (with 0.175 M NaCl, pH 7.4) instead of sample. When calculating the antithrombin activity (aIIa), NMIC derivatives calibrated the test system for unfractionated heparin (HEPARIN-BELMED, 25,000 units) (RUP Belmedpreparations, Minsk, Belarus) [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

New N-Methylimidazole-Functionalized Chitosan Derivatives: Hemocompatibility and Antibacterial Properties

et al. 2023

View full text Add to dashboard Cite

Novel imidazole derivatives of the low molecular weight chitosan N-(2-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-3-ium chitosan chloride (NMIC) were synthesized using copper-catalyzed azide–alkyne cycloaddition (CuAAC). The degrees of substitution (DSs) for the new derivatives were 18–76%. All chitosan derivatives (2000 µg/mL) were completely soluble in water. The antimicrobial activity of the new compounds against E. coli and S. epidermidis was studied. The effect of chitosan derivatives on blood and its components was studied. NMIC samples (DS 34–76%) at a concentration <10 μg/mL had no effect on blood and plasma coagulation. Chitosan derivatives (DS 18–76%) at concentrations of ≥83 μg/mL in blood and ≥116.3 μg/mL in plasma resulted in a prolongation of the clotting time of blood and plasma, positively related to the DS. At concentrations up to 9.1 μg/mL, NMIC did not independently provoke platelet aggregation. The degree of erythrocyte hemolysis upon contact with NMIC samples (2.5–2500 μg/mL) was below 4%. The inhibition of blood/plasma coagulation indicates the promising use of the studied samples to modify the surface of medical materials in order to achieve thromboresistance.

show abstract

“…Dextran sulfate (DexS) is another heavily sulfated semisynthetic polysaccharide that exhibits non-serpin mediated anticoagulant activity (Drozd et al, 2017). Like heparin it can be quantified by its interaction with protamine (Gordon et al, 2021), and it is cleared from the circulation by the HARE scavenger of endothelial cells (Weigel, 2020).…”

Section: G Chemically Sulfated Polysaccharidesmentioning

confidence: 99%